Welcome to factory-direct-buy
Chongqing Saipu Nasi Technology Co., Ltd
Chongqing Saipu Nasi Technology Co., Ltd
Sign in or Join Free Now!

Manufacturer Video

Contact Us

Street Address
North New District
Country/Region
China (Mainland)/Chongqing
Telephone

86-023-13048470428

Anabolic Steroids Hormone Solid 763113-22-0 Olaparib with Radiotherapy
Anabolic Steroids Hormone Solid 763113-22-0 Olaparib with Radiotherapy
  • >= 1  Gram US $1.000
Supply Ability:
1000000 Gram/Grams per Week
Port:
GUANGDONG /CHINA
Email:
Quantity:
Gram
  • Product Detils
  • Company Profile
Quick Details
Place of Origin:
China (Mainland)
Brand Name:
CQSP
Model Number:
763113-22-0
Packaging & Delivery

foil bag, barrel or as your inquiry
Product Description

Anabolic Steroids Hormone Solid 763113-22-0 Olaparib with Radiotherapy

Basic Views:


Product Name Olaparib

Synonyms Olaparib;1-(Cyclopropylcarbonyl)-4-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]piperazine;Olaparib(AZD-2281);Azd 2281;Azd2281;Azd-2281;Ku-0059436;4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one Olaparib

CAS 763113-22-0

Purity 98%

MF C24H23FN4O3

MW 434.469

Appearance White Solid

Brand CQSP STEROID

Price Negotiated

Shipment EMS, FedEx, TNT, DHL, UPSTop Quality Amorolfine Hydrochloride (Amorolfine HCl) 78613-38-4

Delivery within 1 day after we get the payment

Product Categories APIs;API;Inhibitor;Inhibitors

Usage Olaparib is a potent poly(ADP-ribose) polymerase (PARP) inhibitor. Olaparib has been shown to induce significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo. Recent studies show that Olaparib increases radiosensitivity of a lung tumor xenograft, making it a potential candidate for use in combination with radiotherapy.

Reference FOB Price:$1/g

MOQ:10g

Production Capacity:5000kg/month


Shelf life:2 years


HS code;3001200020

More details pls contact:Whatapp:86 13048470428  

Skype/E-mail : summer at chembj.com

Application:

1.Olaparib is a kind of novel poly ADP-ribose polymerase (PARP) inhibitors, including PARP1, PARP2, and PARP3. PARP mediates a DNA-repair mechanism which plays a important role in DNA damage repair and apoptosis, so olaparib specifically targets on the DNA repair mechanism of the targeting cell DNA repair and take effects by attacking the critical vulnerabilities of cancer cells carrying mutations in BRCA1 and BRCA2. Owing to this mechanism, it can be used for the maintenance therapy of patients of severe recurrent ovarian cancer who has breast cancer susceptibility gene (BRCA) mutation as well as being sensitive to platinum drug. Scientists from Harvard Medical School Dana - Farber Cancer Institute have found that the target site of olaparib is the polymerase Q (POLQ, also known POLθ). Those scientists found that a large number of patients of ovarian cancer has the genetic deficiency in the homologous recombination (homologous recombination, HR) repair pathway and dramatic up-regulated expression of POLQ greatly. Since HR is an important repair pathway for repairing broken DNA, they speculated that the major function of POLQ is to compensate for the lack of HR and participate in DNA repair.

2.The experiment has demonstrated that, in normal HR cells, knockout of POLQ would make HR activity increase significantly; while in HR deficient cells, the knockout of POLQ leads to cell death. POLQ contains RAD51 binding domain which can block the process of RAD51-mediated DNA repair. Related research has been published in theFebruary 12, 2015 Naturejournal with Raphael Ceccaldi being the first author of this research.Studies have revealed that about 10% of ovarian cancer patients and 5% of breast cancer patients contain BRCA1 or BRCA2 mutations. Both BRCA1 and BRCA2 belong to tumor suppressor genes as the major components of HR repair pathway. Their mutation suggests the loss of function for the HR repair pathway. In the cancer model of BRCA1 or BRCA2 mutations, blocking the important component for repairing single-strand DNA breaks --PARP can kill the mutated cancer cells. Put the BRCA-deficient mice with POLQ deficient mice for hybridization will cause the death of mouse embryos shortly after birth, which means that the coexistence of two repair pathway deficiency will cause embryonic lethality. 


Send your message to this manufacturer
Email:
Message:
Your message must be between 20-8000 characters
 

© 2015 - 2025, wfdbn.com All rights reserved.